

Company Name: Symbio Pharmaceuticals Limited

July 26, 2013

Securities Code: 4582

Representative: Representative Director  
 President and Chief Executive Officer  
 Fuminori Yoshida  
 Executive Vice President, CFO and  
 Head of Corporate Div.  
 Inquiries: Takashi Shimomura  
 TEL +81(3)5472-1125

## Symbio Announces Revised Financial Forecast

Symbio today announced a revision of its financial forecast for the fiscal year 2013, previously disclosed on February 14, 2013, to reflect current business fundamentals.

### (1) Financial Forecast for Fiscal 2013 (January 1, 2013 to December 31, 2013)

	Net Sales	Operating Profit	Ordinary Profit	Net Profit	Net Profit per Share
	In millions of yen	In millions of yen	In millions of yen	In millions of yen	In millions of yen
Previous Forecast (A)	1,927	(1,889)	(1,922)	(1,926)	(81.03)
Revised Forecast (B)	1,563	(1,743)	(1,749)	(1,753)	(76.10)
Increase/Decrease (B-A)	(364)	146	173	173	—
Percentage Change (%)	(18.9)	—	—	—	—
(Reference) Financial results for the previous year ended December, 2012	1,955	(1,700)	(1,729)	(1,733)	(90.6)

### (2) Rationale for revision

The sales forecast for FY2013 is expected to be 1,563 million yen, 364 million yen lower than budget following review of the current market inventory level of TREAKISYM®. We expect to register a lower net loss of 1,753 million yen for FY2013, mainly due to lower R&D costs than expected in the budget.

\*Any forward-looking statements in this material, including the forecast of financial results, are estimates based on information available at the time and certain assumptions that Symbio's management believes to be reasonable. Actual results may differ substantially from such forecasts due to various factors.